These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12677780)

  • 41. [Relationship between serum asymmetric dimethylarginine and blood pressure in patients with chronic renal failure].
    Zhang WR; Tao LJ; Chen BM
    Hunan Yi Ke Da Xue Xue Bao; 2002 Apr; 27(2):133-4. PubMed ID: 12575339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery.
    Maas R; Dentz L; Schwedhelm E; Thoms W; Kuss O; Hiltmeyer N; Haddad M; Klöss T; Standl T; Böger RH
    Crit Care Med; 2007 Aug; 35(8):1876-81. PubMed ID: 17581491
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Epidemiology of cardiovascular disease in CKD-MBD].
    Di Micco L; Mozzillo GR; Cianciaruso B
    G Ital Nefrol; 2009; 26 Suppl 49():S3-10. PubMed ID: 19941272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction.
    Wierzbicki AS; Solomon H; Lumb PJ; Lyttle K; Lambert-Hammill M; Jackson G
    Atherosclerosis; 2006 Apr; 185(2):421-5. PubMed ID: 16046217
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients.
    Avci E; Coskun S; Cakir E; Kurt Y; Ozgur Akgul E; Bilgi C
    Ren Fail; 2008; 30(8):784-90. PubMed ID: 18791952
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
    Gilinskiĭ MA
    Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epidemiology of cardiovascular risk factors in chronic renal disease.
    Coresh J; Longenecker JC; Miller ER; Young HJ; Klag MJ
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S24-30. PubMed ID: 11443765
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Excess cardiovascular mortality in the uremic patient--what does it teach for other risk factors in the non-renal patient?
    Ritz E; Nowicki M; Wiecek A
    Pol Arch Med Wewn; 1994; 92 Spec No():110-6. PubMed ID: 7731891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
    Portolés J; López-Gómez JM; Aljama P
    Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes.
    Krzyzanowska K; Mittermayer F; Wolzt M; Schernthaner G
    Diabetes Care; 2007 Jul; 30(7):1834-9. PubMed ID: 17456842
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Asymmetrical methylarginine (ADMA) as a cardiovascular risk factor: epidemiological and prospective data].
    Böger RH
    Dtsch Med Wochenschr; 2004 Apr; 129(15):820-4. PubMed ID: 15054688
    [No Abstract]   [Full Text] [Related]  

  • 53. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.
    Desai A; Zhao Y; Warren JS
    Nephrol Dial Transplant; 2008 May; 23(5):1513-20. PubMed ID: 18204093
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis?
    Orlic L; Mikolasevic I; Lukenda V; Racki S; Stimac D; Milic S
    Med Hypotheses; 2014 Dec; 83(6):798-801. PubMed ID: 25456789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for cardiac morbidity and mortality in dialysis patients.
    Foley RN; Parfrey PS
    Curr Opin Nephrol Hypertens; 1994 Nov; 3(6):608-14. PubMed ID: 7881984
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The careful correction of renal insufficiency abnormalities: early is good.
    Zucchelli P
    Nephrol Dial Transplant; 2000; 15 Suppl 2():2-6. PubMed ID: 11051030
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular disease in chronic renal insufficiency.
    Levin A; Foley RN
    Am J Kidney Dis; 2000 Dec; 36(6 Suppl 3):S24-30. PubMed ID: 11118155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comorbidity and cardiovascular risk factors in patients with chronic kidney disease.
    Paparello J; Kshirsagar A; Batlle D
    Semin Nephrol; 2002 Nov; 22(6):494-506. PubMed ID: 12430094
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reducing cardiovascular morbidity and mortality from hypertension in end-stage renal disease.
    Picton ML; Foley RN
    Curr Opin Nephrol Hypertens; 2000 Sep; 9(5):497-500. PubMed ID: 10990367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronic renal failure: a cardiovascular risk factor.
    Fort J
    Kidney Int Suppl; 2005 Dec; (99):S25-9. PubMed ID: 16336573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.